"Despite the challenges, gene therapy is a promising avenue in the quest for a cure," amfAR's Rowena Johnston, Ph.D., says.
Researchers have identified human genes that could be the key to a gene therapy-based HIV treatment.
Mark Mascolini brings clarity to the buzz about the latest broadly neutralizing antibody to make headlines.
In response to user feedback, AIDSinfo is expanding its Drug Database to house more investigational drugs and will now also include investigational therapeutic HIV vaccines.
Lead researchers who are part of the amfAR Institute for HIV Cure Research at UCSF tackled HIV cure questions at a forum on World AIDS Day this year.
The study will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every 8 weeks can safely protect men and transgender women from HIV infection.
This infographic from AVAC details the process for developing long-acting injectables for pre-exposure prophylaxis (PrEP) and treatment.
Top 10 Clinical Developments of 20161. Donald Trump6. Return of the Antibodies2. Switch Frenzy7. Is an Unexpected Low HIV RNA Level Real?3. 2-Drug ART8. Dolutegravir and the Central Nervous System4. Is HIV PrEP at a Tipping Point?9. TAF in Hepatitis ...
Learn about advances in HIV cure research from leaders in HIV science in two Facebook Live events from NIAID's Strategies for an HIV Cure conference.
Scientists from the National Institutes of Health have identified an antibody from an HIV-infected person that potently neutralized 98 percent of HIV isolates tested, including 16 of 20 strains resistant to other antibodies of the same class.